泰和泰证字[2023]PZH-02 号 泰和泰（北京）律师事务所 北京市朝阳区东四环中路 56 号远洋国际中心 A 座 12 层 电话：（010）85865151 传真：（010）85861922 邮政编码：100025 泰和泰（北京）律师事务所关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会法律意见书 泰和泰（北京）律师事务所 关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会 法律意见书 泰和泰（北京）律师事务所 关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会法律意见书 泰和泰证字[2023]PZH-02 号 致：漳州片仔癀药业股份有限公司 泰和泰（北京）律师事务所（以下简称"本所"）接受漳州片仔癀药业股份 有限公司（以下简称"公司"）的委托，指派许军利律师、殷庆莉律师对公司 2023 年第一次临时股东大会（以下简称"本次股东大会"）进行见证，并依据 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东大会规则》（以下简称"《股东大会规则》"）、《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》（以下简称"《规范运 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-024 漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 369 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 413,149,793 | | 3、出席会议的股东所持有表决权股份数占公司有表 | 68.4797 | | 决权股份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主 持情况等。 1 (一) 股东大会召开的时间：2023 年 8 月 9 日 (二) 股东大会召开的地点：漳州市芗城区漳州芗江酒店二楼凌波厅 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有 股份情况： 表决方式符合《公司法》及《漳州片仔癀药业股份有限公司章程》 （以下简称"《公司章程》"）的规定，公司董事黄进明先生主持本次 会议。大会采用网络投票和现场投票相 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-012 漳州片仔癀药业股份有限公司 关于参加福建辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，漳州片仔癀药业股份有限公 司（以下简称"公司"）将参加由福建证监局、福建省上市公司协会 与深圳市全景网络有限公司联合举办的"2023 年福建辖区上市公司 投资者网上集体接待日活动"。现将相关事项公告如下： 本次集体接待日活动将采用网络远程的方式举行，投资者可以登 录"全景路演"网站（http://rs.p5w.net/），或关注微信公众号"全 景财经"，或下载全景路演 APP，参与本次互动交流。 活动时间为 2023 年 5 月 15 日（星期一）16:00 至 17:30。 届时，公司高管将在线就公司 2022 年度及 2023 年第一季度的业 绩情况、公司治理、发展战略、经营状况和可持续发展等投资者关心 的问题，与投资者进行沟通与交流。 欢迎广大投资者踊跃参与！ 特此公告。 漳 ...

2023年第一季度报告 证券代码：600436 证券简称：片仔癀 漳州片仔癀药业股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Financial Performance - The company's operating revenue for 2022 was CNY 8,694,001,504.35, an increase of 8.38% compared to CNY 8,021,550,451.33 in 2021[12]. - The net profit attributable to shareholders of the listed company was CNY 2,472,344,731.55, reflecting a growth of 1.66% from CNY 2,431,899,933.57 in the previous year[12]. - The net cash flow from operating activities surged to CNY 6,873,030,580.06, a significant increase of 1,386.79% compared to CNY 462,272,404.86 in 2021[12]. - The total assets at the end of 2022 reached CNY 14,603,844,518.45, marking a 16.63% increase from CNY 12,521,151,432.34 at the end of 2021[12]. - The net assets attributable to shareholders of the listed company were CNY 11,329,967,292.12, up 16.74% from CNY 9,705,456,064.61 in 2021[12]. - The basic earnings per share for 2022 was CNY 4.10, an increase of 1.74% from CNY 4.03 in 2021[13]. - The weighted average return on net assets decreased to 23.50%, down 4.18 percentage points from 27.68% in the previous year[13]. - The company distributed cash dividends of CNY 754,146,512.50, accounting for 30.50% of the net profit attributable to shareholders[2]. - The company achieved total revenue of 8.694 billion RMB in 2022, an increase of 8.38% year-on-year[38]. - Net profit for the year was 2.523 billion RMB, reflecting a growth of 2.36% compared to the previous year[38]. Revenue and Profit Trends - Total revenue for Q1 2022 was RMB 234,814.28 million, with a net profit attributable to shareholders of RMB 68,928.91 million[15]. - In Q2 2022, total revenue decreased to RMB 207,448.93 million, while net profit attributable to shareholders was RMB 62,507.52 million[15]. - Q3 2022 saw a revenue of RMB 219,313.80 million and a net profit of RMB 73,812.51 million, indicating a recovery from Q2[15]. - Total revenue reached RMB 867,447.81 million, with a year-on-year increase of 8.37%, while total costs amounted to RMB 471,351.08 million, reflecting a year-on-year increase of 19.53%[44]. - The total gross margin for the company was 45.66%, which decreased by 5.07 percentage points compared to the previous year[44]. Research and Development - The company invested 230,034,488.96 yuan in R&D, which is 2.65% of total revenue[56]. - R&D expenses increased by 15.30% year-on-year, reflecting the company's commitment to enhancing its research capabilities[58]. - The company's R&D investment for the reporting period was CNY 23,003.45 million, representing a year-on-year increase of 15.30%[84]. - The R&D investment accounted for 2.65% of the company's operating revenue, while the parent company's R&D investment accounted for 5.24%[84]. - The company has several major R&D projects, including innovative research on modern disease spectra with an investment of CNY 6,524.83 million, which represents 0.75% of operating revenue[85]. Market and Product Development - The company is focusing on the modernization of traditional Chinese medicine, with over 10 clinical studies on its core product, Pizhonghuang, particularly for cancer treatment[20]. - The company is advancing clinical research on Pizhonghuang to establish new indications, including its use in liver cancer treatment[20]. - A total of 40 research projects are underway related to Pizhonghuang, covering pharmacology, efficacy, and toxicology[20]. - The company is committed to enhancing its governance and compliance through various initiatives, including anti-corruption education and supervision[20]. - The company is focusing on transforming its marketing model and precise market positioning to gain a competitive edge in the pharmaceutical industry[69]. Corporate Governance and Compliance - The company has established a comprehensive internal control system, resulting in the eighth edition of the "Management System Compilation" and "Internal Control Manual" to improve operational efficiency[111]. - The company has maintained independence from its controlling shareholder in business, personnel, assets, and finance, ensuring no interference in decision-making[114]. - The company has implemented measures to ensure compliance with legal and regulatory requirements in its governance structure, with no significant discrepancies noted[113]. - The company has successfully elected new directors and supervisors during the annual general meeting, ensuring governance continuity[117]. - The board of directors has established a performance evaluation system for senior management, ensuring accountability and oversight[153]. Environmental and Social Responsibility - The company achieved a 100% compliance rate in environmental monitoring and a 100% guarantee rate for environmental funding in 2022, with all "three wastes" emissions below national standards[29]. - The company has established an environmental protection mechanism and invested 4.57 million RMB in environmental protection during the reporting period[159]. - The company has implemented a comprehensive environmental monitoring plan, with third-party verification of pollutant emissions[171]. - The company has committed to continuous investment in environmental protection and has developed emergency response plans for potential incidents[175]. - The company promotes low-carbon practices among employees, including daily behavior norms and a "clean plate" campaign to reduce waste[176]. Strategic Initiatives and Future Outlook - The company plans to enhance its cosmetics brand strategy with a focus on long-termism and product innovation[34]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan earmarked for potential deals[120]. - The company is positioned to benefit from the ongoing reforms in centralized drug procurement, which are expected to have a profound impact on the pharmaceutical industry[68]. - The company aims to expand its product pipeline and actively engage in the health product market[68]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[120].

Financial Performance - The company's revenue for Q3 2022 was CNY 2,193,137,955.89, representing a decrease of 3.08% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2022 was CNY 738,125,096.32, down 17.64% year-on-year[2] - The basic earnings per share for Q3 2022 was CNY 1.22, reflecting an 18.12% decrease compared to the same period last year[2] - Total operating revenue for the first three quarters of 2022 reached RMB 6,615,770,012.53, an increase of 8.25% compared to RMB 6,111,647,624.71 in the same period of 2021[14] - Operating profit for the first three quarters of 2022 was RMB 2,486,666,408.09, slightly up from RMB 2,435,842,326.43 in the previous year, reflecting a growth of 2.09%[14] - The total profit for Q3 2022 was approximately ¥2.49 billion, compared to ¥2.43 billion in Q3 2021, reflecting an increase of about 2.2%[15] - The net profit for Q3 2022 was approximately ¥2.09 billion, up from ¥2.06 billion in Q3 2021, indicating a growth of around 0.5%[15] - The basic and diluted earnings per share for Q3 2022 were both ¥3.40, compared to ¥3.33 in Q3 2021, representing an increase of 2.1%[16] - The net profit for the first three quarters of 2022 reached ¥2,028,350,590.65, representing an increase of 3.9% from ¥1,952,585,508.90 in the previous year[24] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to CNY 13,513,815,049.25, an increase of 8.15% from the end of the previous year[2] - Total assets as of September 30, 2022, amounted to RMB 13,513,815,049.25, an increase from RMB 12,495,334,742.42 at the end of 2021, representing a growth of 8.16%[12] - Current assets totaled RMB 11,706,478,022.66 as of September 30, 2022, compared to RMB 10,633,421,321.56 at the end of 2021, marking an increase of 10.08%[11] - Total liabilities decreased to RMB 2,133,733,212.87 from RMB 2,358,585,534.93, a reduction of 9.52%[11] - The total liabilities decreased to ¥417,633,917.36 from ¥748,017,862.54, reflecting improved financial health[22] Shareholder Information - Shareholders' equity attributable to the parent company reached CNY 10,897,367,492.25, up 12.29% year-on-year[2] - The company had a total of 120,113 common shareholders at the end of the reporting period[5] - The largest shareholder, Zhangzhou Jiulongjiang Group Co., Ltd., held 51.30% of the shares, totaling 309,522,643 shares[5] - The company reported a total equity of ¥8,045,721,713.68, compared to ¥6,747,384,947.13 in the previous year, indicating growth in shareholder value[22] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was CNY 6,170,796,213.66, showing a significant increase of 858.37% year-on-year[2] - Cash flow from operating activities for the first nine months of 2022 was approximately ¥6.17 billion, a significant increase from ¥643.88 million in the same period of 2021[18] - The company reported a net cash outflow from investing activities of approximately ¥5.54 billion for the first nine months of 2022, compared to a net inflow of ¥82.04 million in the same period of 2021[18] - The company incurred a net cash outflow from investing activities of ¥5,345,460,200.81, contrasting with a net inflow of ¥149,064,194.63 in the previous year[25] - The cash inflow from financing activities for Q3 2022 was approximately ¥1.20 billion, compared to ¥856.83 million in Q3 2021, showing an increase of about 40%[19] Research and Development - Research and development expenses increased to RMB 143,261,715.23 in the first three quarters of 2022, up from RMB 98,249,009.06 in the same period of 2021, indicating a growth of 45.8%[14] - Research and development expenses increased significantly to ¥123,899,232.47, up from ¥82,670,109.68, indicating a focus on innovation[23] Cash and Liquidity - The company's cash and cash equivalents decreased to RMB 2,416,361,509.10 from RMB 7,096,831,080.99, a decline of 65.96%[10] - The total cash and cash equivalents at the end of Q3 2022 were approximately ¥2.33 billion, down from ¥2.56 billion at the end of Q3 2021, showing a decrease of about 8.8%[19] - The cash and cash equivalents at the end of the period were ¥1,276,342,187.92, down from ¥1,544,456,299.94, showing a decrease in liquidity[26] - The company experienced a foreign exchange impact of ¥8,581,738.64 on cash and cash equivalents, compared to a negative impact of ¥2,016,348.18 in the previous year[26] Inventory Management - Inventory as of September 30, 2022, was RMB 2,348,551,450.20, slightly down from RMB 2,437,503,379.48 at the end of 2021, a decrease of 3.67%[10] - The company’s inventory as of September 30, 2022, was approximately ¥1.51 billion, a decrease from ¥1.69 billion at the end of 2021, reflecting a reduction of about 10.7%[21] Dividends and Payouts - The company paid out ¥730,013,824.10 in dividends and interest, an increase from ¥542,985,489.00 in the same period last year[26]

Financial Performance - The company's operating revenue for the first half of 2022 reached ¥4,422,632,056.64, representing a 14.91% increase compared to ¥3,848,706,002.12 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was ¥1,314,364,302.27, up 17.85% from ¥1,115,239,605.23 in the previous year[11]. - The net cash flow from operating activities significantly increased to ¥5,364,583,037.99, a remarkable rise of 1,794.16% compared to ¥283,216,344.17 in the same period last year[11]. - The total assets of the company at the end of the reporting period were ¥13,545,163,644.18, an increase of 8.40% from ¥12,495,334,742.42 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company increased by 5.32% to ¥10,221,163,178.71 from ¥9,705,010,875.84 at the end of the previous year[11]. - Basic earnings per share for the first half of 2022 were ¥2.18, reflecting a 17.84% increase from ¥1.85 in the same period last year[12]. - The weighted average return on net assets decreased by 0.50 percentage points to 12.73% from 13.23% in the previous year[12]. Risk Management - The company has not reported any significant risks that could materially affect its operations during the reporting period[2]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[2]. - The company faces potential risks including policy changes that could affect tax rates, currently benefiting from a reduced corporate income tax rate of 15%[60]. - The company has invested in R&D to maintain its status as a high-tech enterprise, which is crucial for mitigating risks associated with tax policy changes[60]. - The company is actively managing environmental risks through innovation and compliance with stricter regulations[62]. - The company is preparing for potential raw material supply and price risks by strategically increasing procurement reserves[63]. Corporate Governance - The company held two shareholder meetings in the reporting period, with all resolutions passed without dissent[66]. - The first extraordinary shareholder meeting approved various reports and proposals, including the work reports of the sixth board of directors and supervisors[66]. - The company appointed Chen Honghui as the secretary of the board of directors in August 2022[70]. - The company experienced changes in its board and supervisory personnel, with several new appointments made during the reporting period[67][68]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[71]. - The company’s governance structure was improved through the election of new board members and supervisors in January 2022[69]. Environmental Responsibility - The company achieved a 100% compliance rate in environmental monitoring and a 100% guarantee rate for environmental protection funding during the reporting period[38]. - The company was listed as a key pollutant discharge unit in Zhangzhou City for 2021, with all emissions meeting the required standards[72]. - The company reported a total discharge of 0.66454 tons of COD, 0.01321 tons of ammonia nitrogen, and 0.1453 tons of sulfur dioxide, all within regulatory limits[72]. - The company has established a comprehensive hazardous waste management plan for 2022, ensuring proper disposal of industrial solid waste and hazardous waste by qualified companies[75]. - Environmental monitoring results indicate that all pollutants from Pianzaihuang Cosmetics are within the limits set by relevant standards, including noise and odor emissions[75]. - The company has committed to continuous improvement in environmental performance, including regular monitoring and third-party assessments of pollutant emissions[80]. Research and Development - The company has established a management system for drug marketing authorization holders (MAH) since 2021, adding new products like Apixaban tablets in 2022[21]. - The company is focusing on the R&D of innovative traditional Chinese medicine, with plans to enhance the clinical and market value of its key products like Pian Zai Huang[27]. - The company has a strong commitment to technology innovation, being recognized as a national high-tech enterprise and continuously expanding its R&D capabilities[24]. - The company reported a significant increase in R&D expenses, which rose by 82.18% year-on-year, amounting to CNY 11,012.15 million[41]. - The company is actively advancing new drug research, including PZH2111 for intrahepatic cholangiocarcinoma and PZH2108 for cancer pain, among others, establishing a robust pipeline for future growth[28]. Market Expansion and Product Development - The company aims to enhance its core competitiveness by implementing a "multi-core drive, dual development" strategy in the health industry[17]. - The company has successfully launched the "Pian Zai Huang" brand An Gong Niu Huang Wan, which has gained significant consumer trust[19]. - The company is expanding its product line, including various medications for liver disease, colds, and skin conditions, with a valid drug production license until November 2025[19]. - The company’s pharmaceutical distribution business is focused on modern logistics and aims to extend its distribution chain[19]. - The company is expanding its brand influence through high-frequency advertising campaigns, including collaborations with major media outlets and innovative promotional events[34]. Financial Position - The total assets of the company at the end of the reporting period are not explicitly stated but can be inferred to be substantial given the equity figures reported[111]. - The company's total equity reached ¥10,685,559,425.27, compared to ¥10,136,749,207.49, an increase of approximately 5.4%[97]. - The company's retained earnings increased to ¥7,283,359,137.54 from ¥6,699,008,659.37, showing a growth of approximately 8.7%[97]. - The total liabilities increased to ¥2,859,604,218.91, up from ¥2,358,585,534.93, representing a growth of approximately 21.2%[97]. - Cash and cash equivalents decreased to ¥1,853,952,795.22 from ¥5,966,010,997.85, a decline of approximately 68.9%[98]. Social Responsibility - The company is committed to social responsibility, engaging in various community support initiatives and health-related donations during the pandemic[34]. - The company actively supports poverty alleviation and rural revitalization, providing technical support and funding to livestock farmers in collaboration with local governments[85]. - During the reporting period, the company donated funds to 30 underprivileged families and organized various charitable activities, including donations to welfare institutions for children with severe illnesses[85]. - The company continues to focus on high-quality development while fulfilling its social responsibilities[85].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 2,348,142,791.88, representing a year-on-year increase of 17.30%[2] - The net profit attributable to shareholders for the same period was CNY 689,289,146.57, reflecting a growth of 21.93% compared to the previous year[2] - The basic earnings per share (EPS) for Q1 2022 was CNY 1.14, which is an increase of 21.28% year-on-year[2] - Operating profit for Q1 2022 was RMB 832,118,692.18, up 21.8% from RMB 683,337,217.68 in Q1 2021[13] - The company's net profit attributable to shareholders rose to RMB 704,648,052.86, compared to RMB 590,655,369.53 in Q1 2021, marking an increase of 19.3%[13] - The net profit attributable to the parent company's shareholders for Q1 2022 was ¥689,289,146.57, an increase from ¥565,307,136.45 in Q1 2021, representing a growth of approximately 22%[14] - The total comprehensive income attributable to the parent company's owners for Q1 2022 was ¥625,857,897.91, compared to ¥567,241,620.84 in Q1 2021, indicating an increase of about 10.3%[15] - The net profit for Q1 2022 reached ¥691,084,144.41, up 20.2% from ¥575,162,272.14 in the same period last year[23] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 25.50% to CNY 506,073,691.76[2] - Cash flow from operating activities for Q1 2022 was ¥506,073,691.76, down from ¥679,248,836.63 in Q1 2021, a decrease of about 25.5%[17] - Cash and cash equivalents at the end of Q1 2022 amounted to ¥2,830,741,386.28, compared to ¥3,034,285,156.02 at the end of Q1 2021, a decrease of approximately 6.7%[18] - The cash flow from operating activities for Q1 2022 was ¥518,214,482.39, down from ¥751,585,355.56 in Q1 2021, a decrease of 30.9%[24] - The net cash flow from investing activities for Q1 2022 was -¥7,518,050.49, an improvement from -¥13,576,401.16 in Q1 2021[18] - The net cash flow from financing activities for Q1 2022 was -¥74,545,327.48, compared to -¥44,044,774.96 in Q1 2021, indicating a worsening cash flow situation[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 12,873,413,880.91, up 3.03% from the end of the previous year[2] - Total assets as of March 31, 2022, amounted to RMB 12,873,413,880.91, up from RMB 12,495,334,742.42 at the end of 2021[10] - Total liabilities decreased to RMB 2,095,184,288.37 from RMB 2,358,585,534.93, a reduction of 11.1%[11] - The total current assets as of March 31, 2022, were ¥8,169,216,509.74, an increase from ¥7,761,423,118.03 at the end of 2021, representing a growth of about 5.3%[19] - The total liabilities decreased to ¥552,461,237.04 in Q1 2022 from ¥748,017,862.54 in Q1 2021, indicating a reduction of 26.1%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 112,704[5] - The largest shareholder, Zhangzhou Jiulongjiang Group Co., Ltd., held 54.54% of the shares[5] - The equity attributable to shareholders increased by 6.45% to CNY 10,330,868,773.75 compared to the end of the previous year[2] - The total equity attributable to shareholders increased to RMB 10,330,868,773.75 from RMB 9,705,010,875.84, reflecting a growth of 6.4%[11] - The company's total equity increased to ¥9,869,195,976.46 in Q1 2022 from ¥9,245,047,298.96 in Q1 2021, reflecting a growth of 6.7%[21] Research and Development - R&D expenses increased significantly to RMB 78,170,868.25, compared to RMB 22,037,414.40 in the same period last year, reflecting a growth of 254.5%[13] - Research and development expenses increased significantly to ¥73,077,200.50, compared to ¥14,787,937.23 in Q1 2021, reflecting a growth of 393.5%[22]

Financial Performance - The company's operating revenue for 2021 was CNY 8,021,550,451.33, representing a 23.20% increase compared to CNY 6,510,781,957.23 in 2020[14] - The net profit attributable to shareholders for 2021 was CNY 2,431,454,744.80, a 45.46% increase from CNY 1,671,518,667.38 in 2020[14] - The net profit after deducting non-recurring gains and losses was CNY 2,405,941,631.41, up 51.40% from CNY 1,589,128,867.44 in 2020[14] - The company's total operating revenue was RMB 802,155.05 million, with a net profit attributable to shareholders of RMB 243,145.47 million, representing a year-on-year increase of 12.5% and 8.3% respectively[17] - The company achieved a total revenue of 8.02 billion yuan, an increase of 1.51 billion yuan or 23.20% year-on-year[55] - Net profit reached 2.46 billion yuan, up by 775 million yuan or 45.86% compared to the previous year[55] Cash Flow and Assets - The company's net cash flow from operating activities decreased by 68.49% to CNY 462,272,404.86 from CNY 1,467,076,541.32 in 2020[14] - The total assets at the end of 2021 were CNY 12,495,334,742.42, a 22.44% increase from CNY 10,205,569,714.10 at the end of 2020[14] - The net assets attributable to shareholders at the end of 2021 were CNY 9,705,010,875.84, reflecting a 23.44% increase from CNY 7,862,170,023.97 at the end of 2020[14] - The company's cash flow from operating activities showed a significant decline of 68.49%, totaling 462.27 million yuan[57] - Cash and cash equivalents amounted to CNY 709,683.11 million, representing 56.80% of total assets, with a growth of 37.31% from the previous period[81] Research and Development - The company has actively pursued R&D, with over 30 technology projects submitted for approval, including 8 at the national level and 21 at the provincial level[24] - The company plans to enhance its product offerings by focusing on the secondary development of its core product, Pianzaihuang, and the innovation of traditional Chinese medicine and chemical drugs[24] - R&D expenses surged by 104.52% to 199.51 million yuan, reflecting the company's increased investment in research and development[56] - The company reported a total R&D investment of CNY 19,951.07 million, which represents 2.49% of total revenue, reflecting a 104.52% increase year-on-year[106] Market Strategy and Expansion - The company launched new online flagship stores on Tmall and JD.com to enhance profit margins[15] - The company plans to continue strengthening market planning and expanding marketing channels in the future[15] - The company aims to leverage its brand and capital advantages to seek suitable acquisition targets for stable external expansion[22] - The company is actively pursuing external acquisitions to leverage its brand and capital advantages for high-quality development[49] - The company plans to invest approximately 999.08 million RMB in a new technology building, with funding sourced from internal resources[120] Corporate Governance - The company held 9 board meetings and 3 shareholder meetings in 2021, successfully passing all proposed resolutions[22] - The company has established effective communication channels to ensure all shareholders are informed and can participate in major decisions[144] - The company has implemented a comprehensive internal control system to enhance risk management in key areas such as fund management and procurement[143] - The company received an A rating for investor relations management from the Fujian Provincial Association of Listed Companies for the 2020-2021 period[147] Social Responsibility and Community Engagement - The company donated over 700,000 doses of "Qingfei Paidu Decoction" granules to various national departments during the pandemic[41] - The company plans to invest CNY 3 million in rural revitalization projects, including the establishment of an education fund and a community service center[42] - The company has established a volunteer service team with over 450 members to engage in community service activities[43] Environmental Compliance - The company maintained a 100% compliance rate for environmental monitoring and achieved zero environmental accidents in 2021[37] - The company reported a wastewater discharge of 29,750 tons and carbon emissions of 7,185 tCO2e in 2021[200] - The company was listed as a key pollutant discharge unit in Zhangzhou for 2021, adhering to all environmental protection standards without any administrative penalties[198] Employee Engagement and Compensation - The company implemented a performance assessment system for employees, focusing on productivity and incentivizing higher output[185] - The company has established a multi-tiered welfare system, including pension and medical insurance, to enhance employee engagement and retention[185] - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to 5.3428 million yuan[156] Product Development and Innovation - The company is actively developing new products and enhancing its product pipeline, focusing on health products[100] - The company submitted applications for new drugs, including Apixaban tablets for VTE prevention, which received market approval[103] - The company is committed to increasing the development of innovative drugs and actively adjusting its product structure to capture structural opportunities arising from drug procurement and medical insurance directory adjustments[95]

Financial Performance - The company's operating revenue for Q3 2021 was CNY 2,262,941,622.59, representing a year-on-year increase of 24.09%[5] - Net profit attributable to shareholders for Q3 2021 reached CNY 896,223,425.53, a significant increase of 93.08% compared to the same period last year[5] - Basic earnings per share for Q3 2021 were CNY 1.49, reflecting a 93.51% increase year-on-year[5] - Total operating revenue for the first three quarters of 2021 reached CNY 6,111,647,624.71, a 20.5% increase from CNY 5,069,904,020.63 in the same period of 2020[19] - Net profit for the first three quarters of 2021 was CNY 2,060,884,458.83, up 52.2% from CNY 1,352,815,034.62 in the first three quarters of 2020[20] - Operating profit increased to CNY 2,435,842,326.43, compared to CNY 1,587,926,601.21 in the previous year, reflecting a growth of 53.5%[19] - Total comprehensive income for the third quarter of 2021 was CNY 2,074,087,261.81, compared to CNY 1,409,994,755.43 in the same quarter of 2020, marking a 47.0% increase[23] - Basic and diluted earnings per share for the third quarter of 2021 were both CNY 3.33, up from CNY 2.20 in the same quarter of 2020[23] Assets and Liabilities - The total assets at the end of the reporting period were CNY 11,978,301,052.47, an increase of 17.37% from the end of the previous year[5] - As of September 30, 2021, the company's total assets amounted to RMB 11,978,301,052.47, an increase from RMB 10,205,569,714.10 at the end of 2020, reflecting a growth of approximately 17.3%[13] - The company's cash and cash equivalents reached RMB 6,726,143,347.34, up from RMB 5,168,461,763.79, indicating a year-over-year increase of about 30.1%[13] - Total current liabilities increased to RMB 1,938,022,097.12 from RMB 1,800,343,240.35, representing a rise of approximately 7.7%[16] - The total equity attributable to shareholders at the end of the reporting period was CNY 9,344,507,871.00, an increase of 18.85% from the previous year[5] - The company's total liabilities increased to RMB 2,183,367,962.76 from RMB 1,949,014,183.54, reflecting an increase of about 12%[16] - Current assets totaled approximately ¥8.30 billion, a slight decrease of ¥2.95 million compared to the previous period[30] - Total liabilities were approximately ¥2.06 billion, an increase of ¥108.50 million compared to the previous period[32] Shareholder Information - The company reported a total of 115,958 common shareholders at the end of the reporting period[8] - The total equity attributable to shareholders rose to RMB 9,344,507,871.00, compared to RMB 7,862,170,023.97, showing an increase of approximately 18.7%[16] - Shareholders' equity totaled approximately ¥8.26 billion, remaining stable compared to the previous period[33] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was CNY 643,882,541.50, showing a decrease of 56.60% compared to the same period last year[5] - Cash flow from operating activities generated CNY 643,882,541.50, a decrease of 56.5% compared to CNY 1,483,679,415.80 in the first three quarters of 2020[25] - The company reported a net cash outflow from financing activities of CNY -600,747,024.32 in the third quarter of 2021, compared to CNY -498,806,939.34 in the same quarter of 2020[28] - The company’s long-term investments decreased to RMB 343,177,612.14 from RMB 481,200,023.48, representing a decline of approximately 28.7%[14] - The company reported a long-term equity investment of approximately ¥481.20 million[31] Inventory and Borrowings - The company reported inventory levels of RMB 2,222,766,107.21, slightly up from RMB 2,190,938,900.93, indicating a growth of about 1.5%[13] - The company’s inventory stood at approximately ¥2.19 billion, unchanged from the previous period[30] - The company’s short-term borrowings decreased to RMB 692,142,309.76 from RMB 718,384,748.65, reflecting a reduction of approximately 3.6%[16] - The company’s short-term borrowings were approximately ¥718.38 million, remaining stable[32] Marketing and Future Plans - The company expanded its marketing channels by launching new online flagship stores on Tmall and JD.com, contributing to the profit increase[7] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19]